Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest

Entera Bio Ltd. (NASDAQ:ENTX) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totaling 2,403,597 shares, a growth of 87.5% from the September 15th total of 1,281,818 shares. Based on an average daily volume of 464,319 shares, the short-interest ratio is currently 5.2 days. Approximately 1.5% of the shares of the stock are sold short.

Institutional Investors Weigh In On Entera Bio

A hedge fund recently raised its position in Entera Bio stock. Seven Fleet Capital Management LP raised its stake in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 51.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 205,542 shares of the company’s stock after buying an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned about 0.42% of Entera Bio worth $228,000 at the end of the most recent reporting period. 14.11% of the stock is owned by institutional investors.

Entera Bio Price Performance

Shares of NASDAQ ENTX opened at $2.50 on Thursday. Entera Bio has a 12-month low of $0.91 and a 12-month high of $4.20. The company has a market capitalization of $434.81 million, a PE ratio of -7.14 and a beta of 1.40. The firm’s 50-day moving average is $2.89 and its two-hundred day moving average is $2.00.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, analysts forecast that Entera Bio will post -0.40 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wall Street Zen raised Entera Bio to a “sell” rating in a report on Saturday, August 8th. HC Wainwright reissued a “buy” rating on shares of Entera Bio in a report on Wednesday, June 24th. Lifesci Capital initiated coverage on Entera Bio in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price target for the company. Guggenheim began coverage on Entera Bio in a research report on Thursday, September 24th. They issued a “buy” rating and a $11.00 price target for the company. Finally, Cantor Fitzgerald initiated coverage on Entera Bio in a research note on Tuesday, September 22nd. They set an “overweight” rating for the company. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.60.

About Entera Bio

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered biologic medicines. The company’s proprietary platform is designed to enable the oral administration of large-molecule therapies, including peptides and proteins that are traditionally delivered by injection.

Entera Bio’s pipeline has included EB613, an oral formulation of parathyroid hormone fragment (teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral parathyroid hormone product intended for hypoparathyroidism.